Intrastromal versus subconjunctival anti-VEGF agents for treatment of corneal neovascularization: a rabbit study

Basit Öğe Kaydı
dc.authorid0000-0002-4336-2517en_US
dc.authorid0000-0001-9945-793Xen_US
dc.authorid0000-0002-7356-9826
dc.authorid0000-0001-8305-6600
dc.authorid0000-0003-1691-618X
dc.contributor.authorÜçgül, Rukiye Kılıç
dc.contributor.authorÇelebi, Serdal
dc.contributor.authorYılmaz, Niyazi Samet
dc.contributor.authorBukan, Neslihan
dc.contributor.authorÜçgül, Ahmet Yücel
dc.date.accessioned2021-06-23T19:17:07Z
dc.date.available2021-06-23T19:17:07Z
dc.date.issued2020
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractObjective To determine whether subconjunctival or intrastromal administration of anti-VEGF agents is more effective on suture-induced corneal neovascularization (CoNV) in rabbits. Methods CoNV was induced in 48 eyes of 24 New Zealand white rabbits by using an 8/0 silk suture. On the 7th day after suturing, the rabbits were divided into four treatment groups as follows: six rabbits received subconjunctival bevacizumab (group 1), six rabbits received subconjunctival aflibercept (group 2), six rabbits received intrastromal bevacizumab (group 3) and six rabbits received intrastromal aflibercept (group 4). On the 7th and 14th days after suturing, the CoNV area was calculated by standardised analysis of photographs using the Image-J program. On the 14th day after suturing, all rabbits were sacrificed and then corneal tissue was harvested for the analysis of vascular endothelial growth factor (VEGF)-A, VEGF-B and placental growth factor (PIGF) levels. Results On the 7th day after suturing, CoNV areas were 17.10 +/- 2.98, 18.88 +/- 3.78, 17.36 +/- 4.52, 18.57 +/- 4.16 and 17.31 +/- 2.81 mm(2) in the groups 1-4 and control group, respectively. On the 7th day after intervention and removal of suture, CoNV areas were 4.85 +/- 1.99, 6.66 +/- 1.73, 2.83 +/- 1.08, 2.63 +/- 1.16 and 11.93 +/- 2.64 mm(2) in the group 1-4 and control group, respectively. CoNV area was reduced by 88.1% and 82.5% in eyes receiving intrastromal aflibercept and bevacizumab, respectively (both p < 0.001), and by 64.5% and 69.9% in eyes receiving subconjunctival aflibercept and bevacizumab, respectively (both p = 0.001). Conclusion Intrastromal anti-VEGF therapy regressed CoNV more effectively than subconjunctival therapy regardless of the type of anti-VEGF agent.en_US
dc.identifier.doi10.1038/s41433-020-01347-3
dc.identifier.endpage3130
dc.identifier.issn0950-222X
dc.identifier.issue11
dc.identifier.pmid33469129en_US
dc.identifier.scopus2-s2.0-85100213276en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage3123
dc.identifier.urihttps://doi.org/10.1038/s41433-020-01347-3
dc.identifier.urihttps://hdl.handle.net/20.500.12491/5228
dc.identifier.volume35
dc.identifier.wosWOS:000608937400010en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÜçgül, Rukiye Kılıç
dc.institutionauthorÜçgül, Ahmet Yücel
dc.institutionauthorÇelebi, Serdal
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofEyeen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIntrastromalen_US
dc.subjectSubconjunctival
dc.subjectAnti-VEGF
dc.subjectCorneal Neovascularization
dc.titleIntrastromal versus subconjunctival anti-VEGF agents for treatment of corneal neovascularization: a rabbit studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
rukiye-kilic-ucgul.pdf
Boyut:
945.34 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu